RMB, If you want to get a better understanding of how Amarin v Hikma is going to play out, read all of the filings from GSK v Teva. We have the same legal representation. That case is a road map. Use a combination theory, label plus inappropriate advertising, to get past the pleading stage. Then go after the validity of the label through expert testimony during the trial. North is correct that the court could invalidate the "skinny label" on the basis of fraud. That issue has not yet been presented.
Sleven,